The Quantellect read.As of Nov 19, 2026, 12 active firms cover Ideaya Biosciences Inc: 11 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $35.00 to $65.00, a moderate spread. The average target of $51.09 sits 93% above the current $26.49. The rating mix has stayed broadly stable, with Buy-side ratings easing from 14 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.24 next quarter toward $-4.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy1192%
Neutral18%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$51.09
+92.9% upside
Average target across 11 active firms as of Nov 19, 2026 vs $26.49 current
Highest Target$65.00
Average Target$51.09
Lowest Target$35.00
Detailed analyst forecasts for IDYA
Showing 1–12 of 12 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 11 of 12 active firms rate IDYA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IDYA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.24
Range $-1.41 – $-1.04 · 6 analysts · +12% YoY
Next period, 6 analysts expect Ideaya Biosciences Inc to earn $-1.24 a share (range $-1.41 – $-1.04), versus $-1.11 a year earlier. Full-year consensus is $-4.77, growing to $-4.15 the year after.
REVENUE · NEXT QUARTER
$9.2M
Range $0 – $30.1M · 6 analysts · +41% YoY
Revenue is expected to reach $9.2M (range $0 – $30.1M), +40.7% year-over-year. Full-year consensus is $42.4M, rising to $124.5M next year.
Top analysts covering Ideaya Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IDYA.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$45.00+69.9% to target
Overall win rate
52%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$45.00+69.9% to target
Overall win rate
51%
+ Follow
#3
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$45.00+69.9% to target
Overall win rate
47%
+ Follow
#4
Peter Lawson
Barclays · Rank #89
Buy
$40.00+51.0% to target
Overall win rate
45%
+ Follow
#5
Andrew Berens
Leerink Partners · Rank #162
Neutral
$33.00+24.6% to target
Overall win rate
53%
+ Follow
IDYA stock forecast FAQ
What is IDYA's average 12-month price target?+
The 11 active firms with a live target average $51.09 for Ideaya Biosciences Inc over the next 12 months, ranging from a $65.00 high to a $35.00 low, as of Nov 19, 2026.
Is IDYA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 11 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IDYA?+
The Street-high target is $65.00 (Citigroup), and the Street-low is $35.00 (Goldman Sachs). The average of all 11 active-firm targets is $51.09.
How many active Wall Street firms cover IDYA?+
12 active firms have a recognized rating on Ideaya Biosciences Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IDYA?+
Among analysts who currently cover IDYA, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $45.00 target.
What is Ideaya Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-1.24 per share (range $-1.41 – $-1.04) across 6 analysts. Full-year EPS is projected at $-4.77, rising to $-4.15 the following year.
How much revenue is Ideaya Biosciences Inc expected to report next quarter?+
Consensus revenue is $9.2M (range $0 – $30.1M). Full-year revenue is projected at $42.4M, growing to $124.5M next year.
Have analysts been upgrading or downgrading IDYA lately?+
As of Nov 19, 2026, 11 of 12 active firms rate IDYA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IDYA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.